@article{StadionSchuermann2020,
  author    = {Stadion, Mandy and Sch{\"u}rmann, Annette},
  title     = {Intermittierendes Fasten},
  series = {Der Diabetologe},
  volume    = {16},
  journal   = {Der Diabetologe},
  number    = {7},
  publisher = {Springer Medizin},
  address   = {Berlin},
  issn      = {1860-9716},
  doi       = {10.1007/s11428-020-00666-z},
  pages     = {641 -- 646},
  year      = {2020},
  abstract  = {Obesity increases the risk of metabolic disorders and can lead to type 2 diabetes. Therefore, the treatment and prevention of obesity represent important medical challenges. Increased physical activity and a reduction in daily caloric intake of 25-30\% are often recommended. Another possibility is intermittent fasting, by limiting dietary caloric content over certain times, i.e. one or more days a week or for more than 14 h a day. Animal and human studies provide evidence that intermittent fasting in obesity leads to a reduction in body fat mass as well as to improvements of metabolic parameters and insulin sensitivity. These positive effects are mediated not only by the decrease in body mass, but also by the activation of metabolic pathways and cellular processes that are specific for fasting conditions. In this article, we describe the current knowledge about the mechanisms induced by intermittent fasting and present results from randomized controlled human trials.},
  language  = {de}
}